Piper Jaffray Companies reissued their buy rating on shares of Illumina (NASDAQ:ILMN) in a research report sent to investors on Tuesday. Piper Jaffray Companies currently has a $269.00 price target on the life sciences company’s stock.
Other research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Illumina from a hold rating to a buy rating and set a $229.00 price objective for the company in a research note on Friday, October 27th. Vetr raised shares of Illumina from a hold rating to a buy rating and set a $217.50 price objective for the company in a research note on Tuesday, September 19th. Argus raised their price objective on shares of Illumina from $205.00 to $235.00 and gave the stock a buy rating in a research note on Wednesday, September 13th. Deutsche Bank raised shares of Illumina from a hold rating to a buy rating and dropped their price objective for the stock from $195.00 to $160.00 in a research note on Monday, October 23rd. Finally, Canaccord Genuity reissued a buy rating and set a $230.00 price objective (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. Illumina presently has a consensus rating of Buy and a consensus target price of $214.38.
Illumina (NASDAQ ILMN) opened at $244.72 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. Illumina has a 12 month low of $156.50 and a 12 month high of $245.96. The firm has a market cap of $35,045.84, a P/E ratio of 45.83, a PEG ratio of 3.23 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period last year, the company posted $0.97 EPS. The company’s revenue was up 17.6% on a year-over-year basis. research analysts predict that Illumina will post 3.76 earnings per share for the current year.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $210.43, for a total value of $4,208,600.00. Following the transaction, the director now owns 539,176 shares in the company, valued at approximately $113,458,805.68. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction on Saturday, December 29th. The shares were sold at an average price of $217.38, for a total transaction of $271,725.00. Following the completion of the transaction, the director now owns 8,838 shares in the company, valued at approximately $1,921,204.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 137,671 shares of company stock worth $29,485,768. 0.89% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its holdings in shares of Illumina by 3.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 13,790 shares of the life sciences company’s stock valued at $3,013,000 after purchasing an additional 500 shares during the last quarter. Private Asset Management Inc. lifted its holdings in shares of Illumina by 2.2% during the 4th quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock valued at $2,419,000 after acquiring an additional 240 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Illumina by 41.2% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 290,458 shares of the life sciences company’s stock valued at $57,859,000 after acquiring an additional 84,690 shares in the last quarter. Moors & Cabot Inc. lifted its holdings in shares of Illumina by 7.1% during the 3rd quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock valued at $1,497,000 after acquiring an additional 500 shares in the last quarter. Finally, IFM Investors Pty Ltd acquired a new position in shares of Illumina during the 3rd quarter valued at $804,000. Institutional investors own 91.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thestockobserver.com/2018/01/13/illumina-ilmn-stock-rating-reaffirmed-by-piper-jaffray-companies.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.